- Home
- MNPR vs NFE Comparison
MNPR vs NFE Comparison
Compare MNPR & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNPR | NFE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 324.4M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MNPR | NFE |
|---|---|---|
| Price | $58.91 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $107.00 | $5.50 |
| AVG Volume (30 Days) | 160.0K | ★ 6.4M |
| Earning Date | 05-08-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,504,037,000.00 |
| Revenue This Year | N/A | $110.34 |
| Revenue Next Year | N/A | $3.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.40 | $0.56 |
| 52 Week High | $105.00 | $4.96 |
Technical Indicators
Market Signals| Indicator | MNPR | NFE |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 47.54 |
| Support Level | $50.60 | $0.59 |
| Resistance Level | $61.51 | $0.77 |
| Average True Range (ATR) | 4.38 | 0.07 |
| MACD | 0.47 | 0.01 |
| Stochastic Oscillator | 51.18 | 30.23 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.